This site requires the latest version of Macromedia Flash Player.

Cash Balance: $467.8 MM (as of 12/31/07)
Dollars invested in R&D since inception: $2,015,896,000 (as of 9/30/07)
Drugs in pipeline: 9 (plus 1 marketed)
Institutional Ownership: 92.2% (as of 2/08/08)
Number of patients enrolled in PROVE clinical trials: 1,000
Number of patients expected to enroll in TVR Phase 3 pivotal trial: 1,050
2007 Revenue: $198.7 MM
2007 R&D expense: $514.5 MM

2008 Milestones:

✓		Initiate Phase 3 clinical development for telaprevir in treatment-naive and treatment-failure patients
✓		Initiate clinical development of one or more next-generation HCV protease inhibitors
✓		Evaluate telaprevir in important HCV sub-populations
✓		Complete a Phase 2a clinical trial with VX-770 in patients with cystic fibrosis
✓		Initiate a single dose PK and safety trial of VX-809 in patients with cystic fibrosis
✓		Initiate clinical development of VX-509 for the treatment of immune-mediated inflammatory diseases

2007 Achievements:

•		Generated telaprevir Phase 2 clinical data to support transition to Phase 3
•		Began to build commercial infrastructure for telaprevir
•		Began clinical development of telaprevir in HCV sub-populations
•		Began Phase 2 clinical trial of VX-770 in cystic fibrosis (CF)
•		Began Phase 1 clinical trial of VX-809 in cystic fibrosis (CF)